[go: up one dir, main page]

WO2011043564A2 - Composition contenant des extraits de ginseng noir pour prévention ou traitement du cancer du foie - Google Patents

Composition contenant des extraits de ginseng noir pour prévention ou traitement du cancer du foie Download PDF

Info

Publication number
WO2011043564A2
WO2011043564A2 PCT/KR2010/006744 KR2010006744W WO2011043564A2 WO 2011043564 A2 WO2011043564 A2 WO 2011043564A2 KR 2010006744 W KR2010006744 W KR 2010006744W WO 2011043564 A2 WO2011043564 A2 WO 2011043564A2
Authority
WO
WIPO (PCT)
Prior art keywords
ginseng
black
steaming
panax
black ginseng
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2010/006744
Other languages
English (en)
Korean (ko)
Other versions
WO2011043564A3 (fr
Inventor
김항종
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN2010800554591A priority Critical patent/CN102711779A/zh
Publication of WO2011043564A2 publication Critical patent/WO2011043564A2/fr
Publication of WO2011043564A3 publication Critical patent/WO2011043564A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to a method for producing black ginseng by separating steamed ginseng, which is more than four years old, into the body and the rice, dried with white ginseng, and repeated several times.
  • the present invention relates to a method for producing black ginseng having increased benzopyrene stability and Rg 3 component and having a prophylactic or therapeutic effect on liver cancer, and a composition thereof.
  • Ginseng ( ⁇ , ginseng) is a perennial herb of the dicotyledon type Arboraceae, grows in deep mountain forests and grows as a medicinal plant.
  • the root of ginseng is called ginseng because its shape is human. The shape of the roots varies with age, and harvest is done in 4-6 years. Ginseng as it is harvested is called ginseng, and dried ginseng is called white ginseng. Steaming red ginseng makes red ginseng, which is called red ginseng. When the red ginseng is steamed and dried several times, it becomes black ginseng.
  • red ginseng and black ginseng is known to improve the active ingredients beneficial to health compared to fresh ginseng by changing the pharmacological components through steaming and drying process.
  • the main bioactive components of red ginseng and black ginseng are known as Ginsenoside-Rb 1 , Rb 2 , Rc, Rd, Re, Rg 1 , Rg 2 , Rg 3 and Ro contained in saponin.
  • Black ginseng is known to be more enhanced ginsenoside Rg 3 component than in particular red ginseng.
  • Black ginseng is a newly developed product, and since it was recently developed, it is not listed as a regular food, but it contains ginsenoside Rg 3 and can be processed into pouches or concentrates and classified as red ginseng processed foods.
  • Black ginseng has already been shown to be effective in boosting immunity, anticancer and sexual function. In addition, through the experience and research results of the present inventors, it was confirmed that it is effective in hepatitis, diabetes and cirrhosis.
  • the present inventors have developed a method for increasing the ginsenoside component of black ginseng through Korean Patent No. 529475 and again invented a method for enhancing Rg 3 in the ginsenoside component.
  • the present invention utilizes a new method that can further enhance the Rg 3 component as compared to Korean Patent Publication No. 840003, which is known to be able to enhance ginsenoside Rg 3 .
  • the method of the present invention proposes a method for producing black ginseng under conditions that can remove benzopyrene, which is known to be produced in the heating process during the manufacture of black ginseng, to below a safety standard.
  • Benzopyrene is a yellow crystalline solid belonging to the polycyclic aromatic hydrocarbons (PAHs) group, and it is known that carbohydrates, proteins and lipids are produced as incomplete combustion when decomposed at temperatures between 300 and 600 °C in foods. Recently, it is also reported to be produced in processed food below 100 °C.
  • the International Agency for Research on Cancer (IARC) underwent a primary toxicity assessment in 1989 and re-evaluated in August 2006 to classify benzopyrene as the first group of human carcinogens.
  • the present inventors confirmed that the black ginseng extract of the present invention has a selectively excellent effect on liver cancer.
  • black ginseng extract has an anticancer effect, it is known about the effects on cancer or oxidation-related diseases of colorectal cancer of Korean Patent Application Laid-Open No. 2006-83301 and 2008-106077 Korean Patent Publication No. 2006-83301. It is not about selective effects.
  • Still another object of the present invention is to provide a method for producing black ginseng body and rice ginseng, which are effective in preventing or treating liver cancer.
  • the present invention is a method for producing black ginseng by repeating steaming and drying the ginseng,
  • Step 1 washing the ginseng and separating the body and ginseng;
  • Step 2 drying the washed ginseng body and the ginseng so that the moisture content is less than 14%;
  • Step 4 drying the steamed body and rice ginseng at a temperature of 25 ⁇ 50 °C for 3 to 5 hours;
  • Step 6 drying the black ginseng body and black rice ginseng after repeated steaming and drying of step 5 at a temperature of 25 to 50 ° C. to finally have 10% or less of moisture;
  • Ginseng of the first step may be 4-6 years old ginseng.
  • the moisture of the ginseng dried in the second step is preferably about 5 ⁇ 14%.
  • the steaming temperature of the 3 step is preferably 80 ⁇ 90 °C, if less than 80 °C ginsenoside Rg 3 component does not increase much and benzopyrene is not removed well, even if it exceeds 90 °C Rg 3 component also increases Benzopyrene is not removed by the safety regulations.
  • the total number of steaming after the completion of the process 5 to 3 is preferably 6 to 13 times by adding 5 to 12 additional steams to the first steam. If the total number of steams is less than six, the ginsenoside Rg 3 component is not increased much and benzopyrene is not removed as well as the safety regulations. As the total number of steams increases, Rg 3 increases but other ginsenosides fall off or disappear, so the number of steams and temperature must be well controlled.
  • the black ginseng body of the present invention and the pulverized extract or solvent (purified water or ethanol) extract of the ginseng can be used when producing a health food or anti-cancer functional medicines, including tablets, capsules, pills, solutions, etc. .
  • the extract of the black ginseng body and the rice ginseng may be prepared as a powder through lyophilization, hot air drying or spray drying, and may be added to pharmaceutical preparations or foods.
  • Ginseng as defined in the present invention is a perennial plant belonging to the genus Panax, Panax ginseng, Panax quinquefolia, Panax Notoginseng, Panax vietnamensis, Panax vietnamensis, Panax elegathior (Panax elegatior), Panax wangianus or Panax bipinratifidus, preferably Panax ginseng or Panax quinquefolia.
  • the pharmaceutical composition comprising the black ginseng body and the ginseng according to the present invention that can be used as an agent for treating cancer is freeze-dried, hot air-dried or spray-dried the extracts of the black ginseng body and the ginseng powder, granules, Oral formulations such as tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories, and sterile injectable solutions.
  • Carriers, excipients, and diluents that may be included in compositions comprising black ginseng body and rice ginseng include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium Phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
  • Solid preparations for oral administration include tablets, pills, powders, granules, capsules and the like, and such solid preparations may contain at least one excipient such as starch, calcium carbonate, sucrose or lactose, gelatin in the extract. The mixture is prepared.
  • lubricants such as magnesium stearate and talc are also used.
  • Oral liquid preparations include suspensions, solvents, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin.
  • Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories.
  • the non-aqueous solvent and suspending agent propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate and the like can be used.
  • As the base of the suppository witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
  • the dosage of the active ingredient will vary depending on the age, sex and weight of the subject to be treated, the particular disease or pathology to be treated, the severity of the disease or pathology, the route of administration and the judgment of the prescriber. Dosage determination based on these factors is within the level of skill in the art and generally dosages range from 0.001 mg / kg / day to approximately 2000 mg / kg / day. More preferred dosage is 1 mg / kg / day to 100 mg / kg / day. Administration may be administered once a day or may be divided several times. The dosage does not limit the scope of the invention in any aspect.
  • the pharmaceutical composition for preventing and treating liver cancer-related diseases of the present invention comprises 0.1 to 50% by weight of the black ginseng extract based on the total weight of the composition.
  • the extract of the present invention can be administered to mammals such as mice, livestock, humans, etc. by various routes. All modes of administration can be expected, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine dural or cerebrovascular injections. Since the extract of the present invention has little toxicity and side effects, it is a drug that can be used safely even when taken for long periods of time.
  • the present invention provides a health functional food for cancer treatment improvement comprising the black ginseng and black rice ginseng according to the present invention is a food supplement acceptable food supplement.
  • the health functional food of the present invention includes the form of tablets, capsules, pills or liquids, and the food to which the compound of the present invention can be added, for example, various foods, beverages, gums, teas, vitamin complexes, etc. And functional foods.
  • ginsenoside Rg 3 is significantly increased in the black ginseng prepared through the present invention than the black ginseng prepared in the prior art.
  • the amount of ginsenoside Rg 3 increases sequentially as the number of steaming increases, and the formation of the amount is sensitive to temperature and drying conditions.
  • Benzopyrene also known as a carcinogen, has been removed to below safety regulations by reducing its amount through repeated steaming at the temperature and steaming conditions of the present invention.
  • benzopyrene is detected to be 1.0 ppb or more, which is higher than the prescribed value, but it can be confirmed that the amount of benzopyrene decreases below the prescribed value through the steaming process.
  • benzopyrene is produced from pesticides remaining in ginseng as a raw material, and the benzopyrene thus produced is removed through the repeated steaming and drying conditions of the present invention.
  • benzopyrene was also detected in the ginseng before steaming, benzopyrene was detected only when black ginseng was prepared using the ginseng, and no benzopyrene was detected in ginseng from the beginning.
  • the black ginseng with the increased ginsenoside Rg 3 has an excellent anticancer effect against liver cancer. This has established a method for producing black ginseng that is effective in liver cancer-related diseases and safe from carcinogens.
  • FIG. 1 is a flowchart illustrating a process of preparing black ginseng according to the method of the first preferred embodiment.
  • Figure 2 is a graph showing the results of the MTT assay for the cell survival rate of hepatic cancer cell HepG2 of Experimental Example 2-1.
  • Example 1 Preparation of black ginseng main body and rice ginseng and extracts using the same: steaming temperature 85 °C, drying temperature 50 °C, the total number of steaming 13 times>
  • the dried white ginseng was changed to red ginseng and black ginseng to black ginseng, and the black ginseng body and rice were prepared, and the last drying process was completed until the water became less than 10%. Thereafter, the black ginseng body and the ginseng were ground to prepare an extract of the black ginseng body and the rice ginseng.
  • the pulverized black ginseng body and rice ginseng were put into 100 l of purified water having a temperature of 80 ° C., respectively, and stirred for 8 hours at a rotational speed of 60 revolutions per minute, and then precipitated for 3 hours.
  • the precipitated extract was filtered to remove solids, and the filtrate was lyophilized to finally prepare a black ginseng body and a ginseng extract as powder.
  • the black ginseng body and the extract of the ginseng were prepared under the same conditions as in Example 1, but the steaming temperature was 80 ° C.
  • the black ginseng body and the extract of the ginseng were prepared under the same conditions as in Example 1, but the steaming temperature was 90 ° C.
  • the black ginseng body and the extract of the ginseng were prepared under the same conditions as in Example 1, but the total number of steaming was performed only six times.
  • the black ginseng body and the extract of the ginseng were prepared under the same conditions as in Example 1, but the total number of steaming was performed only seven times.
  • the black ginseng body and the extract of the ginseng were prepared under the same conditions as in Example 1, but the total number of steaming was performed only eight times.
  • the black ginseng body and the extract of the ginseng were prepared under the same conditions as in Example 1, but the total number of steaming was performed only 9 times.
  • the black ginseng body and the extract of the ginseng were prepared under the same conditions as in Example 1, but the total number of steaming was performed only 10 times.
  • the black ginseng body and the extract were extracted under the same conditions as in Example 1, but the total number of steaming was performed only 11 times.
  • the black ginseng body and the extract of the ginseng were prepared under the same conditions as in Example 1, but the total number of steaming was performed 12 times.
  • the black ginseng body and the extract of the ginseng were prepared under the same conditions as in Example 1, but the drying temperature was 25 ° C.
  • the black ginseng body and the extract of the ginseng were prepared under the same conditions as in Example 1, but the steaming temperature was 70 ° C.
  • the black ginseng body and the rice extract were prepared under the same conditions as in Example 1, but the steaming temperature was 75 ° C.
  • the black ginseng body and the rice extract were prepared under the same conditions as in Example 1, but the steaming temperature was 95 ° C.
  • the black ginseng body and the extract of the ginseng were prepared under the same conditions as in Example 1, but the total number of steaming was performed only once.
  • the black ginseng body and the extract of the ginseng were prepared under the same conditions as in Example 1, but the total number of steaming was performed twice.
  • the black ginseng body and the extract of the ginseng were prepared under the same conditions as in Example 1, but only three times of total steaming was performed.
  • the black ginseng body and the extract were extracted under the same conditions as in Example 1, but the total number of steaming was performed only four times.
  • the black ginseng body and the extract of the ginseng were prepared under the same conditions as in Example 1, but only five times of total steaming was performed.
  • the black ginseng body and the extract of the ginseng were prepared under the same conditions as in Example 1, but the total number of steaming was performed 14 times.
  • the black ginseng body and the extract of the ginseng were prepared under the same conditions as in Example 1, but drying was performed at 20 ° C.
  • the black ginseng body and the extract of the ginseng were prepared under the same conditions as in Example 1, but drying was performed at 55 ° C.
  • red ginseng root red ginseng body
  • red ginseng extract were prepared using purified water at 80 ° C. in the same manner as the extraction method of Example 1.
  • the ginsenoside components of the black ginseng extract and the red ginseng extract of Comparative Example 4 prepared according to the methods of Examples 1 to 4 and Comparative Examples 1 to 3 were analyzed. Since ginsenoside components are known to be more in the root portion, black and red ginseng were used in this experiment, respectively.
  • ginsenosides The analysis of ginsenosides was carried out in accordance with Food Code [Chapter 4. Food Standards and Standards ⁇ 16.Ginseng Products ⁇ 16-10.Concentrated Red Ginseng (1) Red Ginseng Identification Test High-Speed Liquid Chromatography]. The senoside test method was used, and Table 1 is a table showing the analysis of ginsenoside content of black ginseng and red ginseng.
  • the results of Table 1 confirm that the ginsenoside Rg 3 of black ginseng was significantly increased as the number of steaming was increased, and in particular, a large amount of ginsenoside Rg 3 was increased in at least 8 times and in ginsenosides at 9 or more times. It was confirmed that the Rg 3 content was maintained about the same.
  • the steaming temperature of ginsenosides Rg 3 and Rh 1 was most increased between 80 and 90 ° C around 85 ° C. I could confirm it.
  • the ginsenosides Rg 3 and Rh 1 contents of red ginseng showed significantly lower values.
  • the total amount of irradiated black ginseng of Example 1 was analyzed to be 508.9 mg / g, and the irradiated amount of irradiated with the same amount of irradiated with red ginseng of Comparative Example 4 (72.1 mg / g) was increased during initial steaming. It was confirmed that the increase (not shown in the diagram).
  • the cell survival rate of hepatic cancer cell HepG2 was measured using the black ginseng extract powder of Example 1 and the red ginseng extract powder of Comparative Example 4.
  • Black ginseng was used as a representative of the extract of Example 1 having a high Rg 3 content and black and red ginseng as in Experimental Example 1.
  • the black ginseng extract of Example 1 of the present invention can confirm the 50% inhibitory activity against liver cancer cell proliferation at the concentration of 8 ⁇ g / ml or less, the red ginseng extract of Comparative Example 3 to the liver cancer cell proliferation It can be seen that 50% inhibition against the high concentration of 1000 ⁇ g / ml or more. As a result, the black ginseng prepared by the production method of the present invention can be confirmed to have a selective and excellent anticancer effect on liver cancer cells.
  • HepG2 cells to be transplanted were placed in cell culture flasks using DMEM (Gibco BLR) cell culture medium containing 100 U / ml penicillin, 100 g / ml streptomycin, 10% bovine serum and cultured in a 95% CO 2 37 ° C. cell culture medium. .
  • DMEM Gibco BLR
  • the cells were washed twice with HBSS (Hanks balanced salt solution, Gibco BRL) and collected with 0.2% trypsin.
  • Experimental animals used 9-week old BALB / c nude mice (SLC inc., Shizuoka, Japan), each of which was 9 animals. Each extract was orally administered daily at 300 mg / kg and only purified water was administered to the control group.
  • these nude mice were injected with 1 ⁇ 10 7 HepG2 cells to obtain tumor lines, which were then passaged to the passage group.
  • the tumor mass was recovered in three passages, and then the tumor mass was transplanted to eight passages.
  • Tumor sections were made by cutting the outer areas where rapid division occurred to a certain size (3 ⁇ 3 ⁇ 3 mm) at the expense of animals containing tumors growing rapidly with sufficient blood supply before tumor necrosis occurred.
  • the tumor piece was placed at the end of the trocar and the end was reached to the trunk body side of the rear cell of the animal.
  • the trocar was lightly and quickly rotated out of 360 ° to allow the tumor piece to settle in the desired location and the dissection site was disinfected.
  • the experiment was terminated and the autopsy was performed to determine the weight of solid cancers extracted from each subject, and the actual volume was measured using digital plethysmomether.
  • the black ginseng extract of the present invention was confirmed that the ability to inhibit the weight and tumor volume of the tumor in liver cancer animal model experiments than the red ginseng extract.
  • black ginseng and red ginseng extracts were used in the same manner as in Experiment 1 and Experiment 2.
  • the benzopyrene analysis method is the black ginseng body prepared in Examples 1 to 4 and Comparative Examples 1 to 3 according to the benzopyrene test method of the health functional food (so-called black ginseng) of December 31, 2007 4 g of the extract was extracted and concentrated with dichloromethane, dissolved in hexane, passed through a prolysyl cartridge, dried and dissolved in acetonitrile, and analyzed by high performance liquid chromatography (High Chromatograph). 3-methylcollanthene was used as an internal standard, and a fluorescence detector was used as a detector.
  • the column was used in the reverse phase distribution type (C18 Supelco LC-PAH 4.6mm ⁇ 250mm I.D.) and the analysis conditions are shown in Table 4 below and are shown in Table 5 by repeating five times.
  • Benzopyrene is less than 1.0 ppb below safety regulations.
  • the amount of benzopyrene was also detected in ginseng before steaming, but as expected, the amount of benzopyrene was detected as 1.02 ppb. Because of this, clean ginseng that is not detected benzopyrene was steamed separately before steaming, and black ginseng steamed using ginseng that is not detected by benzopyrene was confirmed that benzopyrene was not detected unlike before (as shown in the diagram). Not).
  • the black ginseng produced using the present invention may be added to medicines or foods and used as a cancer prevention agent, a cancer treatment agent, or the like.
  • the present invention provides a high anticancer drug and a method for preparing a functional food containing a black ginseng extract using a black ginseng body and rice.
  • the above ingredients are mixed and filled in an airtight cloth to prepare a powder.
  • tablets are prepared by tableting according to a conventional method for preparing tablets.
  • the above ingredients are mixed and filled into gelatin capsules to prepare capsules.
  • composition ratio of the above-mentioned vitamin and mineral mixtures is composed of relatively suitable ingredients suitable for health foods in a preferred formulation example, but the compounding ratios may be arbitrarily modified, and the above ingredients are mixed according to a conventional health food manufacturing method.
  • the granules may be prepared and used for preparing a health food composition according to a conventional method.
  • composition ratio is a composition suitable for a preferred beverage in a preferred formulation example
  • the compounding ratio may be arbitrarily modified according to regional and ethnic preferences such as demand hierarchy, demand country, and use purpose.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La présente invention concerne un procédé destiné à augmenter de manière spécifique les ingrédients Rg3 à partir d'ingrédients ginsenosides de ginseng noir. Les extraits de ginseng noir préparés par le procédé montrent une activité anticancéreuse élevée contre les cellules humaines de cancer du foie. En outre, il a été vérifié que le procédé de la présente invention a pour effet de diminuer la teneur en benzopyrène, connue comme étant principalement générée lors du chauffage.
PCT/KR2010/006744 2009-10-07 2010-10-04 Composition contenant des extraits de ginseng noir pour prévention ou traitement du cancer du foie Ceased WO2011043564A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2010800554591A CN102711779A (zh) 2009-10-07 2010-10-04 用于预防或治疗肝癌的包含乌参提取物的组合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2009-0095003 2009-10-07
KR1020090095003A KR100972941B1 (ko) 2009-10-07 2009-10-07 흑삼 추출물을 함유하는 간암 예방 또는 치료용 조성물

Publications (2)

Publication Number Publication Date
WO2011043564A2 true WO2011043564A2 (fr) 2011-04-14
WO2011043564A3 WO2011043564A3 (fr) 2011-09-01

Family

ID=42646131

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/006744 Ceased WO2011043564A2 (fr) 2009-10-07 2010-10-04 Composition contenant des extraits de ginseng noir pour prévention ou traitement du cancer du foie

Country Status (3)

Country Link
KR (1) KR100972941B1 (fr)
CN (1) CN102711779A (fr)
WO (1) WO2011043564A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101369638B1 (ko) 2012-01-04 2014-03-06 주식회사 한국인삼공사 동체 균열이 억제된 홍삼의 제조방법
CN104873558A (zh) * 2015-06-11 2015-09-02 北京凯宾鸿生物医药科技有限公司 一种高含量人参皂苷的黑参的制备方法
CN107737146B (zh) * 2017-11-21 2021-04-02 扬州大学 竹节参片及其制备方法
CN120789139B (zh) * 2025-09-12 2025-12-26 广东万年青制药股份有限公司 一种中药组合物在制备抗肝癌药物中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100529475B1 (ko) * 2002-11-15 2005-11-21 김항종 흑삼과 흑미삼의 제조방법
KR100600795B1 (ko) * 2006-01-18 2006-07-19 (주) 흑삼코리아 진세노사이드 알지쓰리 성분의 함량이 뛰어난 흑삼 및 흑삼농축액
KR100754253B1 (ko) * 2006-05-17 2007-09-03 충남대학교산학협력단 신규한 흑삼의 제조방법 및 이를 함유하는 조성물
KR101127279B1 (ko) * 2006-08-11 2012-03-29 박용진 신규제조방법으로 제조된 흑인삼엽 및 이의 추출물을함유하는 항산화용 조성물
KR100692294B1 (ko) * 2006-08-31 2007-03-12 박춘자 대장암에 대해 항암효과가 뛰어난 흑삼추출물의 제조방법
KR100729214B1 (ko) * 2006-11-07 2007-06-19 (주)고려바이오홍삼 흑삼의 제조방법과 이를 이용하여 제조된 흑삼
WO2008075866A1 (fr) * 2006-12-18 2008-06-26 Yong Jin Park Composition contenant un extrait transformé de panax quinquefolium l. pour la prévention et le traitement du cancer
CN101278954A (zh) * 2007-04-04 2008-10-08 赵方林 一种增加了人参皂苷Rg3含量的人参或西洋参制品及其制备方法
KR101082181B1 (ko) * 2007-05-31 2011-11-09 박용진 신규한 흑홍삼 및 이의 추출물의 제조방법 및 이를 함유하는 조성물
KR100920661B1 (ko) * 2007-10-23 2009-10-08 한국한방식품공사주식회사 사포닌 함량이 높은 흑삼 및 그 제조방법.
KR101093899B1 (ko) * 2008-02-29 2011-12-13 강신정 벤조피렌이 저감된 홍삼 및 흑삼의 제조방법
KR20090095354A (ko) * 2008-03-05 2009-09-09 주식회사 엔유씨전자 흑삼제조기 및 이를 이용한 흑삼제조방법

Also Published As

Publication number Publication date
CN102711779A (zh) 2012-10-03
WO2011043564A3 (fr) 2011-09-01
KR100972941B1 (ko) 2010-07-29

Similar Documents

Publication Publication Date Title
WO2010137846A2 (fr) Composition pour accroître de la biodisponibilité de la saponine
WO2012020892A1 (fr) Extrait de rhus verniciflua stokes ayant une teneur augmentée de composé flavonoïde actif et procédé pour préparer celui-ci
WO2013081419A1 (fr) Composition pharmaceutique pour la prévention ou le traitement de troubles des fonctions cognitives comprenant de la spinosyne
WO2016153211A2 (fr) Procédé de préparation d'extrait d'écorce d"agrumes et composition pour prévenir, soulager ou traiter une lésion hépatique
WO2013089402A1 (fr) Composition comprenant un extrait de gypénoside de gynostemma pentaphyllum (thunb.) makino pour traiter ou prévenir le diabète de type ii, l'obésité ou l'hyperlipidémie
WO2020246777A1 (fr) Procédé de préparation d'un extrait de fruit noni riche en iridoïde ou d'une fraction de celui-ci, procédé de préparation d'extrait de fruit noni riche en matière active d'amélioration immunitaire ou fraction de celui-ci et utilisation d'un extrait de fruit noni ou d'une fraction de celui-ci
WO2018174448A1 (fr) Composition pour le traitement et la prévention du syndrome climactérique contenant un extrait médicinal végétal combiné d'atractylis, de mori fructus, de lyciet commun, de longane, d'achyranthes, d'écorce d'eucommia et d'asperge de cochinchine merr. comme ingrédient actif, et son utilisation
WO2015002391A1 (fr) Composition présentant une fonction d'atténuation du syndrome prémenstruel et des douleurs menstruelles
WO2011043564A2 (fr) Composition contenant des extraits de ginseng noir pour prévention ou traitement du cancer du foie
WO2021091164A1 (fr) Composition pharmaceutique destinée à prévenir ou traiter l'obésité ou l'allergie comprenant un extrait de rose comme ingrédient actif
WO2013141581A1 (fr) Composition pharmaceutique ou aliment naturel comprenant des extraits de fruit de lonicera coerulea var. edulis en tant que principes actifs dans la prévention ou l'amélioration de maladies vasculaires cérébrales ischémiques
WO2014200234A1 (fr) Composition contenant un extrait composite de rehmannia glutinosa et de pueraria lobata destinée à prévenir ou à traiter des symptômes de la ménopause
WO2017183902A1 (fr) Composition contenant des extraits de artemisia capillaris, sanguisorba officinalis et curcuma longa et un agent antiviral, en tant que principes actifs, destinée à prévenir ou traiter une maladie du foie
WO2018208128A1 (fr) Composition pharmaceutique comprenant de la tilianine en tant que principe actif pour le traitement prophylactique ou thérapeutique de la maladie de parkinson
WO2021033994A1 (fr) Composition comprenant un extrait de salvia miltiorrhiza ou de paeonia lactiflora utilisé comme principe actif pour la prévention ou le traitement d'un trouble du métabolisme des lipides
WO2020242113A1 (fr) Composition pour la prévention, le soulagement ou le traitement du syndrome métabolique accompagné de l'obésité et/ou du diabète, contenant, en tant que principe actif, un complexe (complexe ib) d'extrait de groseille indienne et d'extrait d'orge jeune
WO2016190566A2 (fr) Composition pharmaceutique ou aliment naturel fonctionnel pour la prévention et le traitement de maladies métaboliques, contenant un extrait aqueux de pleurotus eryngii var. ferulae (pf.) en tant que principe actif
WO2018190501A1 (fr) Composition anti-inflammatoire contenant un extrait de pédoncule de fleur de ginseng
WO2024122660A1 (fr) Composition d'immunostimulation contenant un extrait de mélange végétal en tant que principe actif
WO2023167565A1 (fr) Composition pour prévenir, améliorer ou traiter des maladies parodontales
WO2018190638A1 (fr) Composition pour la prévention ou le traitement de maladies cornéennes, contenant un extrait de glycine max
WO2022139529A1 (fr) Composition pour la prévention, l'amélioration ou le traitement de la gastrite ou de l'ulcère gastroduodénal comprenant un extrait de cinnamomum cassia, une fraction dudit extrait, un isolat de ladite fraction ou des composés isolés à partir de ladite fraction
WO2022182199A1 (fr) Composition contenant un extrait à l'eau chaude de cassis pour prévenir, soulager ou traiter les maladies du foie gras non alcooliques
WO2017048051A1 (fr) Composition pharmaceutique destinée à prévenir ou à traiter les troubles de la fonction cognitive ou les maladies dégénératives du cerveau
WO2022220458A1 (fr) Composition comprenant un extrait de fruit immature d'aurantii comme ingrédient actif pour la prévention ou le traitement d'un symptôme de la climatère masculin

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080055459.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10822209

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10822209

Country of ref document: EP

Kind code of ref document: A2